STOCK TITAN

Director John Gillard details ADS option stakes in Trinity Biotech (TRIB)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

TRINITY BIOTECH PLC director John Gillard filed an initial statement of beneficial ownership, showing holdings of ADS options and common ADS. The filing lists multiple option grants over TRIB ADS with exercise prices between $2.40 and $13.45, plus 10,000 ADS held directly.

Positive

  • None.

Negative

  • None.
Insider Gillard John
Role Director
Type Security Shares Price Value
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS OPTIONS -- -- --
holding ADS -- -- --
Holdings After Transaction: ADS OPTIONS — 7,500 shares (Direct); ADS — 10,000 shares (Direct)
Footnotes (1)
Direct ADS held 10,000 ADS Direct ownership reported on Form 3
Option block at $13.45 7,500 underlying ADS ADS options, exercise price $13.45, expiring October 23, 2027
Option block at $5.70 40,000 underlying ADS ADS options, exercise price $5.70, expiring December 19, 2029
Option block at $5.45 35,000 underlying ADS ADS options, exercise price $5.45, expiring March 25, 2029
Option block at $2.40 (11 Dec) 43,750 underlying ADS ADS options, exercise price $2.40, expiring December 11, 2030
Option block at $2.40 (19 Dec) 29,167 underlying ADS ADS options, exercise price $2.40, expiring December 19, 2030
ADS OPTIONS financial
"The filing lists holdings of ADS OPTIONS with various exercise prices."
ADS financial
"Gillard also reports 10,000 ADS held directly."
Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.
Form 3 regulatory
"This Form 3 is an initial statement of beneficial ownership."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership financial
"Form 3 provides an initial statement of beneficial ownership."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Gillard John

(Last)(First)(Middle)
TRINITY BIOTECH PLC
IDA BUSINESS PARK, WICKLOW

(Street)
BRAYA98 H5C8

(City)(State)(Zip)

IRELAND

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
TRINITY BIOTECH PLC [ TRIB ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
ADS10,000D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
ADS OPTIONS10/23/202110/23/2027ADS OPTIONS7,500$13.45D
ADS OPTIONS10/23/202210/23/2027ADS OPTIONS7,500$13.45D
ADS OPTIONS01/01/202312/19/2029ADS OPTIONS40,000$5.7D
ADS OPTIONS04/01/202312/19/2029ADS OPTIONS40,000$5.7D
ADS OPTIONS07/01/202312/19/2029ADS OPTIONS40,000$5.7D
ADS OPTIONS10/01/202312/19/2029ADS OPTIONS40,000$5.7D
ADS OPTIONS10/23/202310/23/2027ADS OPTIONS7,500$13.45D
ADS OPTIONS01/01/202412/19/2029ADS OPTIONS40,000$5.7D
ADS OPTIONS01/01/202412/11/2030ADS OPTIONS43,750$2.4D
ADS OPTIONS01/01/202412/19/2030ADS OPTIONS29,167$2.4D
ADS OPTIONS03/25/202403/25/2029ADS OPTIONS35,000$5.45D
ADS OPTIONS04/01/202412/11/2030ADS OPTIONS43,750$2.4D
ADS OPTIONS04/01/202412/19/2030ADS OPTIONS29,167$2.4D
ADS OPTIONS07/01/202412/11/2030ADS OPTIONS43,750$2.4D
ADS OPTIONS07/01/202412/19/2030ADS OPTIONS29,167$2.4D
ADS OPTIONS10/01/202412/11/2030ADS OPTIONS43,750$2.4D
ADS OPTIONS10/01/202412/19/2030ADS OPTIONS29,167$2.4D
ADS OPTIONS10/23/202410/23/2027ADS OPTIONS7,500$13.45D
ADS OPTIONS01/01/202512/11/2030ADS OPTIONS43,750$2.4D
ADS OPTIONS01/01/202512/19/2030ADS OPTIONS29,167$2.4D
ADS OPTIONS03/25/202503/25/2029ADS OPTIONS35,000$5.45D
ADS OPTIONS04/01/202512/11/2030ADS OPTIONS43,750$2.4D
ADS OPTIONS04/01/202512/19/2030ADS OPTIONS29,167$2.4D
ADS OPTIONS07/01/202512/11/2030ADS OPTIONS43,750$2.4D
ADS OPTIONS07/01/202512/19/2030ADS OPTIONS29,167$2.4D
ADS OPTIONS10/01/202512/11/2030ADS OPTIONS43,750$2.4D
ADS OPTIONS10/01/202512/19/2030ADS OPTIONS29,167$2.4D
ADS OPTIONS01/01/202612/19/2030ADS OPTIONS29,167$2.4D
ADS OPTIONS04/01/202612/19/2030ADS OPTIONS29,167$2.4D
ADS OPTIONS07/01/202612/19/2030ADS OPTIONS29,167$2.4D
Explanation of Responses:
/s/ John Gillard04/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does John Gillard’s Form 3 for TRINITY BIOTECH PLC (TRIB) show?

The Form 3 shows John Gillard’s initial beneficial ownership in Trinity Biotech. It lists several ADS option positions at different exercise prices and expiration dates, plus 10,000 American Depositary Shares (ADS) held directly as of the reported date.

How many TRINITY BIOTECH (TRIB) ADS does John Gillard hold directly?

John Gillard reports direct ownership of 10,000 ADS. These are American Depositary Shares of Trinity Biotech held outright, separate from his ADS option awards, which give the right to acquire additional ADS at set exercise prices in future.

What ADS option positions does John Gillard report for TRINITY BIOTECH (TRIB)?

He reports multiple ADS option grants, including blocks with exercise prices of $13.45, $5.70, $5.45 and $2.40. Each grant covers tens of thousands of underlying ADS and has stated expiration dates between 2027 and 2030.

Are there any buys or sells of TRINITY BIOTECH (TRIB) shares in this Form 3?

No buy or sell transactions are reported. The transactions are classified as holdings, and the transaction summary shows zero buy and zero sell counts, indicating this filing simply discloses existing ADS and ADS option positions, not new market activity.

What are the key exercise prices and expirations in Gillard’s TRIB ADS options?

Reported ADS options include exercise prices of $13.45 expiring on October 23, 2027, $5.70 expiring on December 19, 2029, $5.45 expiring on March 25, 2029, and $2.40 expiring on dates through 2030.

Is John Gillard’s ownership in TRINITY BIOTECH (TRIB) direct or indirect?

The filing classifies all reported positions as direct ownership. Both the ADS and ADS options show ownership code “D” for direct, with no nature-of-ownership footnotes describing trusts, partnerships, or other indirect holding structures.